Management Team

Our management team brings together a broad range of industry and sector experience and is composed of highly motivated and committed individuals.

Dr. Torsten Neuefeind

Chief Executive Officer and Co-founder

As one of the company founders, Dr. Neuefeind became the CEO in 1998 following the writing of an award winning (McKinsey & Co) business plan for Proteros. He gained industrial and academic research experience in the field of protein structure analysis at Bayer AG and the Max-Planck-Institutes for Biochemistry, Martinsried. Dr. Neuefeind received a Ph.D. in the area of X-ray protein crystallography on drug targets under the supervision of Prof. Robert Huber. Dr. Neuefeind studied chemistry at the Universities of Marburg and Freiburg, Germany.

Dr. Torsten Hoffmann

Chief Scientific Officer

Dr. Hoffmann has more than 18 years of international scientific and research management experience. Before joining Proteros, Dr. Hoffmann was Chief Scientific Officer at Denmark-based Zealand Pharma A/S and Head of Discovery Chemistry at Roche in Basel. He is inventor of an anti-emetic medicine which received FDA approval as Akynzeo® in 2014. He holds a Ph.D. in Chemistry from the ETH in Zurich, Switzerland with Prof. Dieter Seebach, and did postdoctoral research with Prof. Richard Lerner at The Scripps Research Institute in La Jolla, CA, USA.

Dr. Peter Reinemer, MBA

Chief Operating Officer

Prior to joining Proteros, Dr. Reinemer was Section Head Enabling Technologies at Bayer, Germany and Section Head Screening, Bayer Yakuhin, Japan. He is also co-founder of IMD Natural Solutions, Germany. Previously, he was Managing Director of a Joint venture with Khazanah Nasional/Biotropics, Malaysia. Dr. Reinemer holds a Ph.D. in Biochemistry from the Max-Planck-Institute for Biochemistry, Germany and has completed business school in Austria for an MBA.

Dr. Adrian Schomburg

Chief Technology Officer

Dr. Schomburg is a trained molecular biologist with a strong background in target and disease biology. Previously, he worked for the Pfizer Inc. Epigenetics Unit on the identification and application of innovative targets. He received his Ph.D. from the Max Planck Research School for Molecular Biology, Germany and performed his M.Sc. work at the National Institutes of Health, USA, both in the field of epigenetics.